Abstract
5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 21-27 |
| Number of pages | 7 |
| Journal | Leukemia Research |
| Volume | 42 |
| DOIs | |
| Publication status | Published - Mar 1 2016 |
Fingerprint
Keywords
- 5-Azacytidine
- High risk myelodysplastic syndromes
- Oligoblastic acute myeloid leukemia
- Prognostic indices
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine : A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". / Molteni, Alfredo; Riva, Marta; Borin, L.; Bernardi, Massimo; Pelizzari, Anna Maria; Freyrie, Alessandra; Della Porta, Matteo Giovanni; Nichelatti, Michele; Ravano, Emanuele; Quaresmini, Giulia; Mariotti, Jacopo; Caramazza, Domenica; Ubezio, Marta; Guarco, Simona; Gigli, Federica; Greco, Rosa; Cairoli, Roberto; Morra, Enrica.
In: Leukemia Research, Vol. 42, 01.03.2016, p. 21-27.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine
T2 - A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"
AU - Molteni, Alfredo
AU - Riva, Marta
AU - Borin, L.
AU - Bernardi, Massimo
AU - Pelizzari, Anna Maria
AU - Freyrie, Alessandra
AU - Della Porta, Matteo Giovanni
AU - Nichelatti, Michele
AU - Ravano, Emanuele
AU - Quaresmini, Giulia
AU - Mariotti, Jacopo
AU - Caramazza, Domenica
AU - Ubezio, Marta
AU - Guarco, Simona
AU - Gigli, Federica
AU - Greco, Rosa
AU - Cairoli, Roberto
AU - Morra, Enrica
PY - 2016/3/1
Y1 - 2016/3/1
N2 - 5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
AB - 5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
KW - 5-Azacytidine
KW - High risk myelodysplastic syndromes
KW - Oligoblastic acute myeloid leukemia
KW - Prognostic indices
UR - http://www.scopus.com/inward/record.url?scp=84960845295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960845295&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2016.01.006
DO - 10.1016/j.leukres.2016.01.006
M3 - Article
VL - 42
SP - 21
EP - 27
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
ER -